文献速递脑血管病外科神经重症

ω-3脂肪酸乙酯抑制动脉瘤性蛛网膜下腔出血后脑血管痉挛并改善临床结局

ω-3 Fatty Acids Ethyl Esters Suppress Cerebral Vasospasm and Improve Clinical Outcome Following Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2016-12-18

该研究将2012至2015年100例动脉瘤性蛛网膜下腔出血患者按时期分为两组:2012至2013年45例接受标准治疗,2014至2015年55例前瞻性接受额外ω-3脂肪酸治疗。结果显示ω-3脂肪酸组血管造影性脑血管痉挛和新发梗死频率均显著低于对照组,90天改良Rankin量表评分组间有显著差异,且无相关不良事件。作者认为动脉瘤性蛛网膜下腔出血后给予ω-3脂肪酸可能减少脑血管痉挛频率并可能改善临床结局。

要点

  • ω-3脂肪酸组血管造影性脑血管痉挛12例,显著低于对照组的23例(P=0.004)。
  • ω-3脂肪酸组血管痉挛所致新发梗死5例,显著低于对照组的14例(P=0.011)。
  • 两组90天改良Rankin量表评分有显著差异(P=0.031),且无ω-3脂肪酸相关不良事件。

核心结论

  • 动脉瘤性蛛网膜下腔出血后给予ω-3脂肪酸可能减少脑血管痉挛频率并可能改善临床结局。

研究设计与样本

  • 2012至2015年连续纳入100例动脉瘤性蛛网膜下腔出血患者,按时期分为两组:2012至2013年对照组45例接受标准治疗,2014至2015年ω-3脂肪酸组55例前瞻性接受额外ω-3脂肪酸治疗。

主要发现

  • ω-3脂肪酸组血管造影性脑血管痉挛12例,对照组23例,ω-3脂肪酸组显著低于对照组(P=0.004)。
  • ω-3脂肪酸组血管痉挛所致新发梗死5例,对照组14例,ω-3脂肪酸组显著低于对照组(P=0.011)。
  • 两组发病后90天改良Rankin量表评分有显著差异(P=0.031)。
  • 未观察到与ω-3脂肪酸给药相关的不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Occurrence of cerebral vasospasm after onset of aneurysmal subarachnoid hemorrhage (SAH) is a critical factor determining clinical prognosis. Eicosapentaenoic acid and docosahexaenoic acid, both ω-3 fatty acids (ω-3FA), can suppress cerebral vasospasm, and docosahexaenoic acid can relax vessel vasoconstriction and have neuroprotective effects. We investigated whether administration of ω-3FA prevented cerebral vasospasm occurrence and improved clinical outcomes after aneurysmal SAH. METHODS: From 2012 to 2015, 100 consecutive patients with aneurysmal SAH were divided into 2 periods. Between 2012 and 2013 (control period), 45 patients received standard management. Between 2014 and 2015 (ω-3FA period), 55 patients were prospectively treated with additional ω-3FA. Occurrence of cerebral vasospasm, occurrence of cerebral infarction caused by vasospasm, and modified Rankin Scale scores at 30 days and 90 days after onset of SAH for each period were evaluated and compared. RESULTS: The frequency of angiographic cerebral vasospasm in the ω-3FA period was significantly lower than in the control period (12 patients vs. 23 patients, P = 0.004). The frequency of new infarction caused by vasospasm in the ω-3FA period was also significantly lower than in the control period (5 patients vs. 14 patients, P = 0.011). There was a significant difference in modified Rankin Scale scores at 90 days after onset of SAH between the groups (P = 0.031). No adverse events were associated with ω-3FA administration. CONCLUSIONS: Administration of ω-3FA after aneurysmal SAH may reduce the frequency of cerebral vasospasm and may improve clinical outcomes.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Nakagawa I, Yokoyama S, Omoto K, et al. ω-3 Fatty Acids Ethyl Esters Suppress Cerebral Vasospasm and Improve Clinical Outcome Following Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2016. PMID: 27993744. doi:10.1016/j.wneu.2016.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。